Treating KRAS-mutant NSCLC: latest evidence and clinical consequences

MA04.07 Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy

(2017) Ferdinandos Skoulidis et al.   Journal of Thoracic Oncology

P2.03b-031 Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC

(2017) Pasi Jänne et al.   Journal of Thoracic Oncology

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

(2017) David R. Gandara et al.   Journal of Thoracic Oncology

Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633.

(2017) M. Capelletti et al.   JOURNAL OF CLINICAL ONCOLOGY

Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery

(2016) Stéphane Renaud et al.   BRITISH JOURNAL OF CANCER

miR-29b Mediates NF-κB Signaling in KRAS-Induced Non–Small Cell Lung Cancers

(2016) Stephanie Langsch et al.   CANCER RESEARCH

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer

(2016) K.-J. Tang et al.   CLINICAL CANCER RESEARCH

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1)

(2016) Pasi A. Jänne et al.   Clinical Lung Cancer

Impact ofEGFRmutations andKRASamino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer

(2016) Stéphane Renaud et al.   Future Oncology

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2016) Alona Zer et al.   Journal of Thoracic Oncology

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

(2016) Fabrice Barlesi et al.   LANCET

Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1

(2016) O. A. Kent et al.   MOLECULAR CANCER RESEARCH

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

(2016) Jonathan M. L. Ostrem et al.   NATURE REVIEWS DRUG DISCOVERY

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

Progress on Covalent Inhibition of KRASG12C

(2016) K. D. Westover et al.   Cancer Discovery

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

(2016) M. P. Patricelli et al.   Cancer Discovery

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies

(2016) Wei Pan et al.   Oncotarget

Prognostic and Predictive Value inKRASin Non–Small-Cell Lung Cancer

(2016) Kevin Wood et al.   JAMA Oncology

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†

(2015) G. R. Blumenschein et al.   ANNALS OF ONCOLOGY

KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials

(2015) Min Ying et al.   Asian Pacific Journal of Cancer Prevention

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases

(2015) Stéphane Renaud et al.   BRITISH JOURNAL OF CANCER

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

(2015) P A Jänne et al.   BRITISH JOURNAL OF CANCER

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

(2015) A. Calles et al.   CLINICAL CANCER RESEARCH

MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer

(2015) Mick D. Edmonds et al.   JOURNAL OF CLINICAL INVESTIGATION

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer

(2015) Antonio Calles et al.   Journal of Thoracic Oncology

Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas

(2015) Helena A. Yu et al.   Journal of Thoracic Oncology

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

(2015) M B Schabath et al.   ONCOGENE

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy

(2015) Anna K. Brady et al.   Oncotarget

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells

(2015) Elisa Caiola et al.   Oncotarget

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications

(2015) Biagio Ricciuti et al.   Expert Review of Respiratory Medicine

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma

(2014) Benjamin Izar et al.   Journal of Thoracic Oncology

KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma

(2014) Ernest Nadal et al.   Journal of Thoracic Oncology

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

The mutational landscapes of genetic and chemical models of Kras-driven lung cancer

(2014) Peter M. K. Westcott et al.   NATURE

Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

(2013) Frances A. Shepherd et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

(2013) Daquan Meng et al.   LUNG CANCER

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort

(2012) Chiara Scoccianti et al.   EUROPEAN RESPIRATORY JOURNAL

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

(2012) Nathan T. Ihle et al.   JNCI-Journal of the National Cancer Institute

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

(2012) Pasi A Jänne et al.   LANCET ONCOLOGY

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

(2012) Giulio Metro et al.   LUNG CANCER

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

(2012) Zhao Chen et al.   NATURE

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

(2011) M. C. Garassino et al.   ANNALS OF ONCOLOGY

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement

(2011) Hye Ryun Kim et al.   CANCER

Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway

(2010) O. A. Kent et al.   GENES & DEVELOPMENT

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

(2008) G. J. Riely et al.   CLINICAL CANCER RESEARCH

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE